Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Table 2
Second- to third-line treatment sequencing.
Second-Line Regimens
Third-Line Regimen Compositions
Regimen Composition
No. Patients
BOR
LEN
THAL
BOR + LEN
BOR + THAL
Other Regimens
No Treatment
Bortezomib (BOR)
45
→
1
22
2
0
0
6
14
Lenalidomide (LEN)
110
→
24
3
1
0
1
33
48
Thalidomide (THAL)
13
→
2
1
0
0
0
3
7
BOR + LEN
3
→
1
2
0
0
0
0
0
BOR + THAL
4
→
0
3
0
0
0
0
1
Other regimens
17
→
2
2
2
0
0
3
8
Total
192
→
30
33
5
0
1
45
78
Listed regimen compositions are irrespective of concomitant dexamethasone use.
